Abstract
A crucial need exists for reliable Alzheimers disease (AD) diagnostic and prognostic tests. Given its intimate communication with the brain, the cerebrospinal fluid (CSF) has been surveyed intensively for reliable AD biomarkers. The heterogeneity of AD pathology and the unavoidable difficulties associated with the clinical diagnosis and differentiation of this dementia from other pathologies have confounded biomarker studies in antemortem CSF samples. Using postmortem ventricular CSF (V-CSF) pools, two-dimensional difference gel electrophoresis (2D DIGE) analyses revealed a set of proteins that showed significant differences between neuropathologically-diagnosed AD and elderly nondemented controls (NDC), as well as subjects with non-AD dementias. The 2D DIGE system identified a set of 21 different protein biomarkers. This panel of proteins probably reflects fundamental pathological changes that are divergent from both normal aging and non-AD dementias.
Keywords: Alzheimer's disease, cerebrospinal fluid, proteomics, DIGE, biomarkers
Current Alzheimer Research
Title: Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects
Volume: 6 Issue: 4
Author(s): Chera L. Maarouf, Tracy M. Andacht, Tyler A. Kokjohn, Eduardo M. Castano, Lucia I. Sue, Thomas G. Beach and Alex E. Roher
Affiliation:
Keywords: Alzheimer's disease, cerebrospinal fluid, proteomics, DIGE, biomarkers
Abstract: A crucial need exists for reliable Alzheimers disease (AD) diagnostic and prognostic tests. Given its intimate communication with the brain, the cerebrospinal fluid (CSF) has been surveyed intensively for reliable AD biomarkers. The heterogeneity of AD pathology and the unavoidable difficulties associated with the clinical diagnosis and differentiation of this dementia from other pathologies have confounded biomarker studies in antemortem CSF samples. Using postmortem ventricular CSF (V-CSF) pools, two-dimensional difference gel electrophoresis (2D DIGE) analyses revealed a set of proteins that showed significant differences between neuropathologically-diagnosed AD and elderly nondemented controls (NDC), as well as subjects with non-AD dementias. The 2D DIGE system identified a set of 21 different protein biomarkers. This panel of proteins probably reflects fundamental pathological changes that are divergent from both normal aging and non-AD dementias.
Export Options
About this article
Cite this article as:
Maarouf L. Chera, Andacht M. Tracy, Kokjohn A. Tyler, Castano M. Eduardo, Sue I. Lucia, Beach G. Thomas and Roher E. Alex, Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects, Current Alzheimer Research 2009; 6 (4) . https://dx.doi.org/10.2174/156720509788929318
DOI https://dx.doi.org/10.2174/156720509788929318 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Depression and Anxiety Levels Increase Chronic Musculoskeletal Pain in Patients with Alzheimer's Disease
Current Alzheimer Research Severe Mental Disorders from a Cognitive-Behavioural Perspective: A Comprehensive Review from Conceptualization to Intervention
Current Psychiatry Reviews Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach
Current Proteomics Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Editorial (Alzheimer’s Disease and Frail Syndrome: Features Overlap Predictive of Poor Outcome)
CNS & Neurological Disorders - Drug Targets DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Drugs Made of RNA: Development and Application of Engineered RNAs for Gene Therapy
Mini-Reviews in Medicinal Chemistry Pharmacological Approaches of Neurofibrillary Degeneration
Current Alzheimer Research Syntheses and In-Vitro Evaluation of Novel Adamantane Based γ-Secretase Inhibitors
Current Medicinal Chemistry